RESUMEN
Patients with human epidermal growth factor receptor 2 (HER2) overexpression or amplification in gastric and esophagogastic adenocarcinoma can significantly benefit from anti-HER2 therapies. Presently, various humanized monoclonal antibodies such as trastuzumab and pertuzumab, alongside diverse anti-HER2 antibody drug conjugates (trastuzumab emtansine, disitamab vedotin, trastuzumab deruxtecan, ARX788), and tyrosine kinase inhibitors (lapatinib, afatinib, pyrotinib), are employed either as monotherapy or in combination settings for advanced gastric and esophagogastic adenocarcinoma. These therapeutic modalities have demonstrated promising clinical efficacy in clinical trials, thereby ameliorating patients' prognosis and enhancing life quality. Further exploration on the efficacy and safety of novel HER2-targeted agents and combined therapeutic regimens in clinical practice holds the promise of furnishing more efficacious strategies for treating HER2-positive advanced gastric and esophagogastic adenocarcinoma.